Quantcast

Latest Low-density lipoprotein Stories

2014-07-30 08:33:01

Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo...

2014-07-30 08:32:55

- Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor - PARIS and TARRYTOWN, N.Y., July 30, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to...

2014-07-23 23:08:24

Diet Doc’s new cholesterol diet plans focus on helping people in any part of the country lose weight fast and improve their health by reducing bad cholesterol levels Dallas, TX (PRWEB) July 23, 2014 Being overweight is no longer a mere cosmetic concern. Almost every day, new research suggests that eating a diet high in processed and sugar-laden foods significantly affects overall general health and increases the risk for a host of diseases and weight related conditions, including...

2014-07-21 12:24:55

Agents That Reduce the Incidence of Cardiovascular Adverse Events Remain a Key Unmet Need for Both Physicians and Payers, According to Findings from Decision Resources Group BURLINGTON, Mass., July 21, 2014 /PRNewswire/ -- Decision Resources Group finds that Amgen's evolocumab (AMG-145) is set to become the clinical gold-standard among statin add-on therapies used to treat patients with dyslipidemia. The competitive advantages this proprotein convertase subtilisin/kexin type 9 (PCSK9)...

2014-07-17 08:28:35

CARLSBAD, Calif., July 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-APO(a)(Rx) in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease. Patients with high levels of Lp(a) have an increased risk of atherosclerosis, coronary heart disease, aortic stenosis, heart attack and stroke. ISIS-APO(a)(Rx) is designed to reduce Lp(a) by inhibiting the production of...

2014-07-09 08:29:03

INDIANAPOLIS, July 9, 2014 /PRNewswire/ -- Chek Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products, announced today that it has signed a marketing, sales, and distribution agreement with Independent Medical Co-Op, Inc. (IMCO), one of the premier associations for independent medical distributors. IMCO is a cooperative association of over 140 medical supply distributors that serve the physician, hospital,...

2014-07-07 16:00:15

European League Against Rheumatism Intake of monounsaturated fatty acids and cholesterol influence disease activity in RA and OA respectively Two new studies presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) have helped clarify the relationship between the dietary intake of monounsaturated fatty acids and cholesterol with disease activity in rheumatoid arthritis (RA) and osteoarthritis (OA) respectively. In the TOMORROW study, daily intake of...

2014-07-07 08:27:28

VISTA, Calif. and HARTFORD, Conn., July 7, 2014 /PRNewswire/ -- AutoGenomics, Inc, a leader in automated microarray technology for molecular diagnostics, and Genomas, a biomedical company enabling DNA-guided medicine for personal healthcare, announced today that they have signed an agreement to jointly develop genetic tests and DNA-guided diagnostic systems for optimal selection of statins and for improved delivery of statin therapy for the treatment of cardiovascular disease, obesity...

2014-06-27 23:05:56

As hormone levels change during the transition to menopause, the quality of a woman’s cholesterol carriers degrades, leaving her at greater risk for heart disease, researchers at the University of Pittsburgh Graduate School of Public Health discovered. Pittsburgh, Pennsylvania (PRWEB) June 27, 2014 As hormone levels change during the transition to menopause, the quality of a woman’s cholesterol carriers degrades, leaving her at greater risk for heart disease, researchers at the...

2014-06-25 08:30:43

The lives of millions of Americans are potentially at risk. NEW YORK, June 25, 2014 /PRNewswire-USNewswire/ -- The EPA Drug Initiative (EPADI) urges the FDA to thoughtfully consider new and almost irrefutable proof that high triglycerides are a significant risk factor contributing to cardiovascular disease-related death and morbidity. http://photos.prnewswire.com/prnvar/20140625/121320 This past week, two independent studies were published in the prestigious New England Journal of...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related